2.625

3.85% -0.105

Cervomed Inc (CRVO)

Overview News Price History Discussions Forecast Stock Split

Cervomed Inc stock is traded at $2.625, with a volume of 396.90K. It is down -3.85% in the last 24 hours and down -14.77% over the past month. CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Previous Close:

$2.73

Open:

$2.82

24h Volume:

396.90K

Relative Volume:

0.08

Market Cap:

$39.69M

Revenue:

$2.09M

Net Income/Loss:

$-30.04M

P/E Ratio:

-0.8031

EPS:

-3.2685

Net Cash Flow:

$-27.57M

1W Performance:

-8.22%

1M Performance:

-14.77%

6M Performance:

-42.18%

1Y Performance:

-74.06%

1-Day Range:

$2.55

$2.82

1-Week Range:

$2.55

$3.20

52-Week Range:

$2.13

$11.25

Cervomed Inc Stock (CRVO) Company Profile

Name

Cervomed Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(617) 744-4400

Address

20 PARK PLAZA, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-14

Latest SEC Filings

CRVO's Discussions on Twitter

Compare CRVO vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRVO Cervomed Inc	2.625	41.28M	2.09M	-30.04M	-27.57M	-3.2685
VRTX Vertex Pharmaceuticals Inc	515.63	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	807.01	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	991.71	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	213.05	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.46	39.31B	5.76B	514.49M	1.10B	4.4813

Cervomed Inc Stock (CRVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-25	Initiated	Cantor Fitzgerald	Overweight
Mar-13-25	Upgrade	Chardan Capital Markets	Neutral → Buy
Dec-17-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-11-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-11-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-10-24	Downgrade	D. Boral Capital	Buy → Hold
Dec-06-24	Initiated	ROTH MKM	Buy
Dec-05-24	Initiated	H.C. Wainwright	Buy
Sep-18-24	Initiated	Chardan Capital Markets	Buy
Jul-26-24	Initiated	Morgan Stanley	Overweight
Feb-15-24	Initiated	Canaccord Genuity	Buy
Nov-17-20	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-21-18	Initiated	H.C. Wainwright	Buy

View All

Cervomed Inc Stock (CRVO) Latest News

12:24 PM

SABBY MANAGEMENT, LLC's CervoMed Inc(CRVO) Holding History - GuruFocus

12:24 PM

Aug 15, 2026

CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - Stocktwits

Aug 15, 2026

Aug 14, 2026

CervoMed (CRVO): RA Capital discloses 8.6% stake through 1.27M warrant shares - Stock Titan

Aug 14, 2026

CervoMed (CRVO) holders CVI and Heights report 0% stake in amended filing - Stock Titan

Aug 14, 2026

Woodline Partners (CRVO) discloses 5.1% beneficial stake in CervoMed common stock - Stock Titan

Aug 14, 2026

Armistice Capital discloses 9.53% CervoMed (CRVO) ownership via Master Fund - Stock Titan

Aug 14, 2026

Aug 12, 2026

CRVO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus

Aug 12, 2026

CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $18 - Moomoo

Aug 12, 2026

Aug 11, 2026

CervoMed at Canaccord Genuity conference: dLB push gains ground By Investing.com - Investing.com Canada

Aug 11, 2026

CRVO: Phase III-ready DLB drug shows strong clinical data; pipeline expands into PPA and ALS - TradingView

Aug 11, 2026

Aug 10, 2026

JonesTrading Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $12 - Moomoo

Aug 10, 2026

CervoMed reports Q2 2026: $24.9M cash position, net loss $6.6M; advancing neflamapimod toward Phase 3 - TradingView

Aug 10, 2026

CervoMed (NASDAQ: CRVO) details Q2 2026 loss, cash runway and DLB program - Stock Titan

Aug 10, 2026

Canaccord cuts CervoMed stock price target on funding uncertainty By Investing.com - Investing.com India

Aug 10, 2026

Canaccord cuts CervoMed stock price target on funding uncertainty - Investing.com

Aug 10, 2026

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times

Aug 10, 2026

CervoMed Q2 net loss lower than estimates as costs drop - TradingView

Aug 10, 2026

CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $18 - Moomoo

Aug 10, 2026

CRVO Q2'26 Earnings: revenue estimate is 50.00K USD - TradingView

Aug 10, 2026

CERVOMED INC : CANACCORD GENUITY CUTS TARGET PRICE TO $18 FROM $27 - Bitget

Aug 10, 2026

Aug 07, 2026

CervoMed Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 07, 2026

CervoMed Inc. 2026: Revenue $0 Net income ($6.57M), EPS ($0.64) — 10-Q Summary - TradingView

Aug 07, 2026

CRVO: Raised $20.5M in June 2026 to fund R&D and strategic partnership for Phase 3 DLB trial - TradingView

Aug 07, 2026

CervoMed (NASDAQ: CRVO) raises $20.5M, ends Q2 with $24.9M cash - Stock Titan

Aug 07, 2026

CRVO: Neflamapimod progresses to Phase 3 for DLB, with strong cash position and key milestones ahead - TradingView

Aug 07, 2026